ClinicalTrials.gg
Active, not recruitingNCT06946797CheckMate-1533Updated May 14, 2026

A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Nivolumab and Ipilimumab in Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Active, not recruiting at 38 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 44 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
54th of 120
76 · median 66
Started
2025
with 9 others
Phase 2
66 of 120
16 open now
Primary completion
2027-02
later than 18 of 43 live
Registered
110th of 120
by date
Lead sponsor
28 of 120
Bristol-Myers Squibb

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 54th largest by planned enrollment, is one of 10 that started in 2025, is one of 66 in phase 2, reaches primary completion later than 18 of the 43 other live ones, and was the 110th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate two dosing regimens of subcutaneous Nivolumab in combination with intravenous Ipilimumab and chemotherapy in participants with previously untreated metastatic or recurrent Non-Small Cell Lung Cancer (NSCLC)

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Nivolumab
  • Ipilimumab
  • Checkmate-1533
  • CA2091533
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have confirmed stage IV or recurrent non-small cell lung cancer (NSCLC) (as defined by the 9th edition of the IASLC Lung Cancer Staging Guidelines) of squamous or non-squamous histology.
  • Participants must have no prior systemic anti-cancer treatment (including EGFR, ALK, ROS-1, BRAF, RET, and NTRK inhibitors) given as primary therapy for advanced or disease.
  • Participants with prior definitive chemoradiation for locally advanced disease is permitted as long as the last administration of chemotherapy or radiotherapy (whichever was given last) occurred at least 6 months prior to randomization. Participants with locally advanced disease with recurrence after chemoradiation therapy (stage III disease, specifically refers to patients with no curative options) are eligible to enroll.
  • Participants with prior or neoadjuvant chemotherapy for early-stage lung cancer are permitted if completed at least 6 months prior to randomization.
  • Participants must have an (ECOG) Performance Status ≤ 1 at screening and confirmed prior to randomization.
  • Participants must have by CT or MRI per (RECIST) 1.1 criteria with radiographic tumor assessment performed within 28 days of randomization.

Exclusion criteria

Exclusion Criteria

  • Participants must not have any prior treatment with an , anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
  • Participants must not have any known driver mutations with available targeted therapy (including but not limited to EGFR mutations, ALK translocations, ROS-1 translocations and known BRAFV600E, that are sensitive to available targeted inhibitor therapy; participants with a known activating RET mutations and NTRK fusion gene alterations).
  • Participants must not have any untreated central nervous system (CNS)
  • Participants must not have (carcinomatous meningitis).
  • Participants must not have any active, known or suspected disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  • Participants with previous (except non-melanoma skin cancers, and in situ cancers such as the following: bladder, gastric, colon, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to randomization and no additional therapy is required or anticipated to be required during the study period.
  • Participants must not have a condition requiring systemic treatment with either (>10 mg daily prednisone equivalent) within 14 days or other medications within 30 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
  • Participants must not have any history of interstitial lung disease or pneumonitis that required oral or IV glucocorticoids to assist with management.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Arm A

    Drug: Nivolumab · Drug: Ipilimumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Pemetrexed · Drug: Cisplatin

  • Experimental
    Arm B

    Drug: Nivolumab · Drug: Ipilimumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Pemetrexed · Drug: Cisplatin

Interventions

  • Specified dose on specified days

    Also known as: BMS-986298

  • Specified dose on specified days

    Also known as: Yervoy

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Maximum observed serum concentration (Cmax) of subcutaneous Nivolumab in serum

    Time frame: Up to 3 weeks

  2. Time to peak concentration (Tmax) of subcutaneous Nivolumab in serum

    Time frame: Up to 3 weeks

  3. Area under the concentration-time curve within a dosing interval (AUC(TAU)) of subcutaneous Nivolumab in serum

    Time frame: Up to 3 weeks

  4. Concentration at the end of a dosing interval (Ctau) of subcutaneous Nivolumab in serum

    Time frame: Up to 3 weeks

  5. Trough observed concentration (Ctrough) of subcutaneous Nivolumab

    Time frame: At Cycle 7 Day 1 (Week 18)

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to approximately 2.5 years

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to approximately 2.5 years

  3. Number of participants with drug related AEs

    Time frame: Up to approximately 2.5 years

  4. Number of participants with Immune Mediated Adverse Events (IMAEs)

    Time frame: Up to approximately 2.5 years

  5. Number of participants with AEs leading to discontinuation

    Time frame: Up to approximately 2.5 years

  6. Number of deaths

    Time frame: Up to approximately 2.5 years

  7. Number of participants with anti-nivolumab antibodies

    Time frame: Up to approximately 2.5 years

  8. Number of participants with anti-ipilimumab antibodies

    Time frame: Up to approximately 2.5 years

  9. Number of participants with neutralizing antibodies

    Time frame: Up to approximately 2.5 years

  10. Cmax of intravenous Ipilimumab in serum

    Time frame: Up to 6 weeks

  11. Tmax of intravenous Ipilimumab in serum

    Time frame: Up to 6 weeks

  12. AUC(TAU) of intravenous Ipilimumab in serum

    Time frame: Up to 6 weeks

  13. Ctau of intravenous Ipilimumab in serum

    Time frame: Up to 6 weeks

07

Study locations

38 sites
  • Local Institution - 0032
    Anchorage, Alaska 99508, United States
  • Local Institution - 0062
    Los Angeles, California 90033, United States
  • Local Institution - 0063
    Boise, Idaho 83702, United States
  • Local Institution - 0052
    Boise, Idaho 83706, United States
  • Local Institution - 0064
    Post Falls, Idaho 83854, United States
  • Local Institution - 0047
    Cleveland, Ohio 44106, United States
  • Local Institution - 0033
    Cleveland, Ohio 44109, United States
  • Local Institution - 0051
    Allentown, Pennsylvania 18103, United States
  • Local Institution - 0041
    Brasília, Federal District 70200-730, Brazil
  • Local Institution - 0043
    Belo Horizonte, Minas Gerais 30380-490, Brazil
  • Local Institution - 0038
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Local Institution - 0037
    Barretos, São Paulo 14784400, Brazil
  • Local Institution - 0034
    São Paulo, 01246-000, Brazil
  • Local Institution - 0067
    Santiago, Santiago Metropolitan 8420383, Chile
  • Local Institution - 0065
    Dijon, Côte-d'Or 21079, France
  • Local Institution - 0003
    Suresnes, Hauts-de-Seine 92151, France
  • Local Institution - 0010
    Paris, Île-de-France Region 75014, France
  • Local Institution - 0012
    Athens, Attikí 115 27, Greece
  • Local Institution - 0013
    Chaïdári, Attikí 12462, Greece
  • Local Institution - 0011
    Thessaloniki, Kentrikí Makedonía 540 07, Greece
  • Local Institution - 0014
    Larissa, Thessalía 41110, Greece
  • Local Institution - 0015
    Meldola, Emilia-Romagna 47014, Italy
  • Local Institution - 0057
    Udine, Friuli Venezia Giulia 33100, Italy
  • Local Institution - 0020
    Bergamo, Lombardy 24127, Italy
  • Local Institution - 0019
    Florence, Tuscany 50134, Italy
  • Local Institution - 0017
    Novara, 28100, Italy
  • Local Institution - 0081
    Warsaw, Masovian Voivodeship 03-411, Poland
  • Local Institution - 0080
    Prabuty, Pomeranian Voivodeship 82-550, Poland
  • Local Institution - 0079
    Lodz, Łódź Voivodeship 93-338, Poland
  • Local Institution - 0073
    Bucharest, Bucharest 022328, Romania
  • Local Institution - 0076
    Florești, Cluj 407280, Romania
  • Local Institution - 0077
    Craiova, Dolj 200542, Romania
  • Local Institution - 0075
    Bucharest, 020335, Romania
  • Local Institution - 0074
    Cluj-Napoca, 400015, Romania
  • Local Institution - 0078
    Iași, 700483, Romania
  • Local Institution - 0031
    Soweto, Gauteng 2013, South Africa
  • Local Institution - 0009
    Sandton, GP 2196, South Africa
  • Local Institution - 0084
    Rondebosch, Western Cape 7700, South Africa
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Feb 2027, 16 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 16 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2025
First posted
Apr 27, 2025
StartActual
Sep 19, 2025
Primary completionEst.
Feb 5, 2027
CompletionEst.
Oct 25, 2028
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06946797
Responsible party
Sponsor
First posted
Apr 27, 2025
Start date
Sep 19, 2025
Primary completion
Feb 5, 2027 (estimated)
Completion
Oct 25, 2028 (estimated)
Last update
May 14, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion